News search

E.g., 07/10/2024
E.g., 07/10/2024
Figure
Research
13 Sep 2024

RESILIENCE is a clinical trial funded by the European Commission (H2020 Programme) that aims to reduce the prevalence of heart failure in cancer survivors

ESC_Congress
CNIC researchers
Research
30 Aug 2024

Two studies carried out at the CNIC provide key information about a newly identified cardiovascular risk factor, clonal hematopoiesis, and its treatment with the ancient medication colchicine

De izda. a dcha.: Gema González, Estefanía Núñez, Sergio Callejas, Juan Carlos Silla, Enrique Lara-Pezzi, Valentín Fuster, Fátima Sánchez Cabo, José Javier Fuster, Ana Dopazo, Borja Ibáñez, Marta Cortés, Alberto Benguría y Antonio Quesada.
Research
21 Jun 2023

A new CNIC study shows that low-grade systemic inflammation triggered by subcinical atherosclerosis accelerates epigenetic aging in otherwise healthy young individuals

La figura muestra imágenes mediante resonancia magnética cardíaca (A y B) y tomografía computarizada (C y D) de un corazón en diástole (A y C) y sístole (B y D) para el cálculo de la función de ambos ventrículos. VD: Ventrículo derecho; VI: Ventrículo izquierdo.
Research
12 Dec 2022

The results of the SPHERE-HF study are published in the European Journal of Heart Failure. SPHERE-HF is a multicenter academic clinical trial led by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Hospital Clínic de Barcelona

Los complejos I, III, y IV de la cadena de transporte electrónico mitocondrial se asocian formando grandes estructuras llamadas supercomplejos.  SCAF1 determina la asociación entre complejos de la cadena de transporte mitocondrial.
Research
18 Oct 2022

A study, published in Nature Metabolism, is the first to demonstrate the key role played by mitochondria in adapting metabolism to different energy demands in humans

Valentín Fuster
Research
26 Aug 2022

The results of the SECURE trial, coordinated by CNIC were presented in a Hot Line session at the European Society of Cardiology meeting (ESC 2022) in Barcelona and published at the NEJM

Participants who followed the TANSNIP-PESA program (orange line) showed an improvement in lifestyle measures and cardiovascular health compared with participants in the control group (who did not participate in the intervention; blue line). The Y-axis shows changes in the Fuster -BEWAT lifestyle and cardiovascular risk score with respect to the baseline value.
Research
26 Jul 2022

Adherence to a workplace cardiovascular health-promotion program improves lifestyle and risk factors in healthy individuals